While block randomization has been shown to be a more frequently used form of trial randomization design, the use of dynamic randomization has been shown to have optimal treatment group balancing results.
A novel adaptive-block method of randomization to maximize the efficiency of overall treatment group balance, while maintaining balance at investigational centers in smaller sized studies, is proposed.
Two of the most important elements to the integrity of a controlled clinical trial are the patient randomization and the treatment blinding. With a focus on block pattern distribution, four methods of randomization list creation are analyzed.
How new technology can impact cardiac imaging in oncology clinical trials and have broader implications for patient safety.
Survey drills down on the preferences and experiences of clinical trial site personnel in critical function areas such as site initiation and monitoring, training, sponsor interaction, and patient recruitment and retention.
Survey drills down on the preferences and experiences of clinical trial site personnel in critical function areas such as site initiation and monitoring, training, sponsor interaction, and patient recruitment and retention.
Survey drills down on the preferences and experiences of clinical trial site personnel in critical function areas such as site initiation and monitoring, training, sponsor interaction, and patient recruitment and retention.
Survey drills down on the preferences and experiences of clinical trial site personnel in critical function areas such as site initiation and monitoring, training, sponsor interaction, and patient recruitment and retention.
Because of the growing rate of voice assistant applications, such as Alexa, healthcare and life sciences organizations are beginning to design a range of scenarios for deploying these voice assistant platforms in the clinical trial setting.
Clinical trials using electronic Clinical Outcome Assessments (eCOA) benefit from compliance rates 300% higher than paper-based studies - but some sponsor shy away from eCOA adoption due to a misconception that paper diaries are cheaper. Read our eBook to understand the frequently neglected cost calculations proving that eCOA is the cost-effective and superior data collection solution for many clinical trials.
Using strategic planning to address hurdles in biosimilar development programs from the outset.
Using strategic planning to address hurdles in biosimilar development programs from the outset.
The disconnect coordinating and connecting interested patients to clinical trials is an ongoing struggle.
This article focuses on the 3 essential factors that have a significant impact on the outcome of any inspection or audit. The author applies this primarily to GCP (Good Clinical Practice) inspections, but the principles are universal, being applicable to any government inspection such as the FDA (U.S. Food & Drug Administration) or industry QA (Quality Assurance) audit.
Worldwide Clinical Trials recently announced the results of a survey that evaluated the perceptions of clinical trial site investigators who use electronic clinical outcome assessment (eCOA) technologies.
Solutions to overcoming the most frequent missteps when collecting valuable spirometry data in respiratory studies.
Solutions to overcoming the most frequent missteps when collecting valuable spirometry data in respiratory studies.
Solutions to overcoming the most frequent missteps when collecting valuable spirometry data in respiratory studies.
Solutions to overcoming the most frequent missteps when collecting valuable spirometry data in respiratory studies.
As the popularity of personalized medicine grows the role of the CRO continues to evolve.
Discover how evolving clinical trial trends are reshaping patient and site experiences—and the steps sponsors can take to stay ahead—in this conversation with uMotif CEO Steve Rosenberg at SCOPE Summit 2025.
Pediatric trials now feature increased modeling and analytics for safer drug dosing and response.
Pediatric trials now feature increased modeling and analytics for safer drug dosing and response.
Drug developers are using surrogate endpoints to monitor the effectiveness of immunotherapies, taking into account the differences between immunotherapy and traditional treatments.
How the adoption of electronic clinical outcome assessment in trials can drive increased communication and patient reporting of events.